ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
11 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.3K
|
324K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
1 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.3K
|
324K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
6 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
1.3K
|
324K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
7 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
1.3K
|
324K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
pi065509
|
82 |
12K |
5 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
82
|
12K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Walk to Defeat MND
|
|
pi065509
|
26 |
7.5K |
3 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
26
|
7.5K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
pi065509
|
261 |
63K |
4 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
261
|
63K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
pi065509
|
261 |
63K |
6 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
63K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
9 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
1.3K
|
324K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
pi065509
|
77 |
18K |
12 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
18K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
12 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
1.3K
|
324K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
196 |
36K |
4 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
196
|
36K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Mainstream media is GO
|
|
pi065509
|
31 |
11K |
13 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
31
|
11K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
pi065509
|
33 |
8.5K |
9 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
33
|
8.5K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
4 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
1.3K
|
324K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
196 |
36K |
3 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
196
|
36K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
196 |
36K |
4 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
196
|
36K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
pi065509
|
100 |
26K |
15 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
100
|
26K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Big Pharma buyouts.
|
|
pi065509
|
39 |
9.3K |
8 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
9.3K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
3 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
1.3K
|
324K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
pi065509
|
58 |
15K |
22 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
58
|
15K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
pi065509
|
77 |
19K |
11 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
77
|
19K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
pi065509
|
77 |
19K |
4 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
77
|
19K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
12 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
1.3K
|
324K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
5 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
1.3K
|
324K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
12 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
1.3K
|
324K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
5 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
1.3K
|
324K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
pi065509
|
317 |
79K |
3 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
317
|
79K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
pi065509
|
317 |
79K |
4 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
317
|
79K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
pi065509
|
317 |
79K |
19 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
317
|
79K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
6 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
1.3K
|
324K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
4 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
1.3K
|
324K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
8 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
1.3K
|
324K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
pi065509
|
152 |
45K |
8 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
152
|
45K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
pi065509
|
209 |
49K |
3 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
49K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
12 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.3K
|
324K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
17 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.3K
|
324K
|
17
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
16 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.3K
|
324K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
18 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.3K
|
324K
|
18
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
11 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
1.3K
|
324K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Outlines Pathway to Accelerated Approval for MPL in MND
|
|
pi065509
|
58 |
15K |
14 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
58
|
15K
|
14
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
12 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
1.3K
|
324K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.3K |
324K |
9 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
1.3K
|
324K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
pi065509
|
323 |
75K |
2 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
323
|
75K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
pi065509
|
323 |
75K |
6 |
04/02/24 |
04/02/24 |
ASX - By Stock
|
323
|
75K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
pi065509
|
323 |
75K |
17 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
323
|
75K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
pi065509
|
323 |
75K |
15 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
75K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
107K |
6 |
26/01/24 |
26/01/24 |
ASX - By Stock
|
430
|
107K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
107K |
9 |
23/01/24 |
23/01/24 |
ASX - By Stock
|
430
|
107K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
pi065509
|
430 |
107K |
9 |
23/01/24 |
23/01/24 |
ASX - By Stock
|
430
|
107K
|
9
|
|